Literature DB >> 24488593

Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.

Annarosa Del Mistro1, Helena Frayle, Antonio Ferro, Susanna Callegaro, Annamaria Del Sole, Anna Stomeo, Emanuela Cirillo, Chiara Fedato, Silvana Pagni, Luisa Barzon, Manuel Zorzi.   

Abstract

OBJECTIVE: Cervical cancer screening by human papillomavirus (HPV) testing requires the use of additional triage and follow-up analyses. We evaluated women's compliance with and the performance of this strategy in a routine setting.
SETTING: Five cervical service screening programmes in North-East Italy.
METHODS: Eligible women aged 25-64 invited for a new screening episode underwent HPV testing for high risk types (hrHPV by Hybrid Capture 2) and cytology triage. Women with positive HPV and cytology results were referred for colposcopy; women with positive HPV but negative cytology results were referred to 1-year repeat hrHPV testing.
RESULTS: Of 46,694 women screened by HPV testing up to December 2011, 3,211 (6.9%) tested hrHPV positive; 45% of these had a positive triage cytology. Those with negative cytology were invited for 1-yr repeat testing. Compliance with invitation was 61.6% at baseline and 85.3% at 1-yr repeat. Rate of persistent hrHPV positivity was 58% (830/1,435). Colposcopy performed in women with a positive hrHPV test at 1-yr repeat accounted for 36% of all colposcopies performed within the screening programmes. Cumulatively, a histological high-grade lesion was detected in 276 women (5.9‰ detection rate), 234 at baseline (85%), and 42 (15%) at 1-yr repeat.
CONCLUSIONS: Compliance with hrHPV-based screening programmes was high both at baseline and at 1-yr repeat. Compared with the randomized trials, a higher proportion of triage cytology was read as positive, and only a small number of high-grade lesions were detected among the group of hrHPV positive cytology negative women who repeated testing 1-yr after baseline.

Entities:  

Keywords:  HPV; follow-up; organized screening; triage

Mesh:

Year:  2014        PMID: 24488593     DOI: 10.1177/0969141314522219

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  12 in total

1.  Cervical cancer screening opportunities for Guinea-Bissau.

Authors:  Ivo Julião; Joana Savva-Bordalo; Nuno Lunet
Journal:  Porto Biomed J       Date:  2017-04-18

2.  Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.

Authors:  Paolo Giorgi Rossi; Simonetta Bisanzi; Elena Allia; Alessandra Mongia; Francesca Carozzi; Anna Gillio-Tos; Laura De Marco; Guglielmo Ronco; Daniela Gustinucci; Annarosa Del Mistro; Helena Frayle; Anna Iossa; Giulia Fantacci; Giampaolo Pompeo; Elena Cesarini; Simonetta Bulletti; Basilio Passamonti; Martina Rizzi; Maria Gabriella Penon; Alessandra Barca; Maria Benevolo
Journal:  J Clin Microbiol       Date:  2017-01-18       Impact factor: 5.948

3.  Evaluation of the management of Hr-HPV+/PapTest- women: results at 1-year recall.

Authors:  Caterina Chiappetta; Chiara Puggioni; Eugenio Lendaro; Jessica Cacciotti; Roberto Zaralli; Giovanna Migliore; Paola Bellardini; Vincenzo Petrozza; Carlo Della Rocca; Claudio Di Cristofano
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

4.  HPV prevalence and risk of pre-cancer and cancer in regular immigrants in Italy: results from HPV DNA test-based screening pilot programs.

Authors:  Cinzia Campari; Chiara Fedato; Alessio Petrelli; Manuel Zorzi; Carla Cogo; Adele Caprioglio; Federica Gallo; Livia Giordano; Serena Domenighini; Luigi Pasquale; Sonia Prandi; Marco Zappa; Paolo Giorgi Rossi
Journal:  Infect Agent Cancer       Date:  2015-05-07       Impact factor: 2.965

5.  Self-sampling to increase participation in cervical cancer screening: an RCT comparing home mailing, distribution in pharmacies, and recall letter.

Authors:  P Giorgi Rossi; C Fortunato; P Barbarino; S Boveri; S Caroli; A Del Mistro; A Ferro; C Giammaria; M Manfredi; T Moretto; A Pasquini; M Sideri; M C Tufi; C Cogo; E Altobelli
Journal:  Br J Cancer       Date:  2015-01-29       Impact factor: 7.640

6.  Efficacy of self-sampling in promoting participation to cervical cancer screening also in subsequent round.

Authors:  Annarosa Del Mistro; Helena Frayle; Antonio Ferro; Gianpiero Fantin; Emma Altobelli; Paolo Giorgi Rossi
Journal:  Prev Med Rep       Date:  2016-12-23

7.  Discriminating Performance of Early Uterine and Cervical Artery Pulsatility and Resistivity In Pre-Invasive Cervical Lesions.

Authors:  Ozan Doğan; Çiğdem Pulatoğlu; Alper Başbuğ; Aşkı Ellibeş Kaya; Murat Yassa
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2018-09-04

8.  Primary cervical screening with high risk human papillomavirus testing: observational study.

Authors:  Matejka Rebolj; Janet Rimmer; Karin Denton; John Tidy; Christopher Mathews; Kay Ellis; John Smith; Chris Evans; Thomas Giles; Viki Frew; Xenia Tyler; Alexandra Sargent; Janet Parker; Miles Holbrook; Katherine Hunt; Penny Tidbury; Tanya Levine; David Smith; Julietta Patnick; Ruth Stubbs; Sue Moss; Henry Kitchener
Journal:  BMJ       Date:  2019-02-06

9.  HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system.

Authors:  Helena Frayle; Silvia Gori; Martina Rizzi; Bianca Nives Graziani; Elisa Vian; Paolo Giorgi Rossi; Annarosa Del Mistro
Journal:  BMC Womens Health       Date:  2019-03-25       Impact factor: 2.809

10.  HPV Testing for Cervical Cancer in Romania: High-Risk HPV Prevalence among Ethnic Subpopulations and Regions.

Authors:  Minodora Bianca Ilisiu; Dana Hashim; Trude Andreassen; Nathalie C Støer; Florian Nicula; Elisabete Weiderpass
Journal:  Ann Glob Health       Date:  2019-06-20       Impact factor: 2.462

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.